Arimidex® 1 mg film-coated tablets

DRUG4 trials

Sponsors

Astrazeneca AB, Region Oerebro Laen, Fundacion Grupo Espanol De Investigacion En Cancer De Mama, Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS

Conditions

Advanced Breast Cancer in older patientsEarly Breast CancerMetastatic Breast Cancerbreast cancer

Phase 1

A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)

Active, not recruitingCTIS2023-505690-33-00

Astrazeneca ABMetastatic Breast Cancer

Start: 2022-03-11Target: 12Updated: 2026-01-21

Phase 2

Optimization of De-EscalatiON strategies in early breast cancer

Not yet recruitingCTIS2026-527524-27-00

Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCSbreast cancer

Target: 1Updated: 2026-09-14

Phase 3

IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-controlled trial (IMPORTANT trial)

RecruitingCTIS2023-506620-87-00

Region Oerebro LaenAdvanced Breast Cancer in older patients

Start: 2024-01-25Target: 495Updated: 2025-07-10

Phase 4

Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6 inhibitors. "The EX-AI study"

Not yet recruitingCTIS2025-522848-40-00

Fundacion Grupo Espanol De Investigacion En Cancer De MamaEarly Breast Cancer

Target: 74Updated: 2025-12-29